Related Insights

How to raise startup funds in a tough market — according to a life science investor


Corporate investors remain key pillars of life sciences and healthcare

Ariana Ognibene, Jonathan Norris

Top life science investment trends for early-stage startups

Ben Johnson

SVB's 2022 healthtech report reveals strong investment opportunity in mental health

Christopher Moniz

Healthcare industry sectors: An overview of 2022

Jonathan Norris

6 legal considerations for life science and healthcare startups

Ben Johnson

About the Author

Bill Sideris is a director of Life Science and Healthcare, and he provides comprehensive financial products and services as well as flexible lending solutions to Northeast healthtech and medtech clients at every stage of development.

Before this role, he was part of SVB Securities, performing valuations and advising Life Science and Healthcare clients on their M&A strategy. Prior to joining SVB, Bill spent time as an R&D Engineer, developing medical devices for ophthalmic and cardiovascular indications in both Fortune 500 and start-up organizations.

Bill graduated with a professional doctorate degree in engineering from the Technical University of Delft and a master of science degree in biomedical engineering from the University of Houston.